A cohort study based on the population in Brazil disclosed that 78% of patients with ankylosing spondylitis (AS) initiated anti-TNF drug treatment at no charge, with a median monthly per capita cost of $1650 [81]. Here, TNF is linked to ankylosing spondylitis.